Description

Tesamorelin 10mg, 20mg

Research Grade Peptide

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) engineered for enhanced stability and receptor interaction in controlled laboratory environments. It has been widely studied for its ability to stimulate endogenous growth hormone (GH) release through activation of pituitary GHRH receptors.

Unlike exogenous growth hormone, Tesamorelin functions upstream within the endocrine signaling cascade by promoting the body’s natural GH secretion process. This receptor-mediated mechanism requires an intact hypothalamic–pituitary axis for physiological response and has been a primary focus of endocrine research.

Tesamorelin is available in both 10mg and 20mg vial options to accommodate varying research designs and study parameters.

Mechanism of Action (Research Overview)

GHRH Receptor Activation
Tesamorelin binds to growth hormone–releasing hormone receptors located in the anterior pituitary, initiating intracellular signaling pathways that stimulate endogenous GH release.

Downstream IGF-1 Modulation
In research settings, increases in GH secretion have been associated with measurable changes in downstream biomarkers such as insulin-like growth factor 1 (IGF-1) and IGF binding protein-3 (IGFBP-3), commonly used endpoints in endocrine studies.

Pulsatile GH Secretion Research
Tesamorelin has been examined for its ability to enhance naturally occurring pulsatile GH patterns rather than delivering exogenous hormone directly, making it of interest in physiological secretion modeling.

Structural Stability
Its modified peptide structure is designed to reduce enzymatic degradation relative to native GHRH, allowing for extended pharmacodynamic activity in research contexts.

Research Focus Areas

Tesamorelin has been explored in peer-reviewed studies and controlled laboratory settings across multiple endocrine and metabolic pathways. Areas of scientific investigation have included:

• Growth Hormone Axis Dynamics
  Evaluation of endogenous GH release patterns following receptor activation and analysis of pulsatile secretion behavior.

• IGF-1 and IGFBP-3 Measurement
  Monitoring of downstream GH-axis biomarkers in structured clinical research environments.

• Metabolic Signaling Pathways
  Investigation of GH-mediated signaling mechanisms related to lipid metabolism and glucose regulation models.

• Body Composition Study Endpoints
  Controlled research trials have evaluated measurable parameters such as adipose tissue distribution and lean mass metrics within defined study populations.

• Endocrine Selectivity
  Assessment of receptor-specific activity and broader pituitary hormone responses under monitored research conditions.

These research focus areas reflect study endpoints evaluated in published literature and are provided for informational context only.

Key Research Characteristics

• Synthetic GHRH analog

• Studied for pituitary receptor activation and endogenous GH release

• Evaluated for effects on IGF-1 and IGFBP-3 biomarkers

• Commonly researched in endocrine and metabolic signaling models

• Lyophilized (freeze-dried) for stability and storage

Product Specifications

• Compound: Tesamorelin

• Available Sizes: 10mg or 20mg vial

• Form: Lyophilized powder

• Purity: High-purity, lab-tested

• Storage: Store refrigerated after reconstitution

Why Fit Aminos

Fit Aminos supplies research-grade peptides manufactured under strict quality control standards to ensure purity, consistency, and reliability. Each batch is tested to support accurate and repeatable laboratory research outcomes.

Important Notice

This product is for research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.